The apolipoprotein E ε4 allele (APOE ε4) is a genetic risk factor for neurodegenerative diseases. The potential of lipid metabolism as a biomarker in conjunction with APOE ε4 for the evaluation of dementia with Lewy bodies (DLB) warrants further investigation.
Objective
The study aimed to investigate the association between APOE ε4 and lipid metabolism in DLB.
Methods
This was a cross-sectional observational study that included a total of 171 DLB patients diagnosed based on established clinical consensus criteria. Strict inclusion and exclusion criteria were used in this study. APOE genotypes and blood lipid levels were determined using unified standards. IBM SPSS Statistics software was used for statistical analysis.
Results
In patients with mild and moderate CDR, APOE ε4 carriers had significantly higher CHOL and LDL-C levels compared to non-carriers. In the 70–79 age group, APOE ε4 carriers demonstrated higher LDL-C (2.94 ± 0.83 mmol/L versus 2.47 ± 0.97 mmol/L, q = 0.0480) and CHOL (4.88 ± 1.05 mmol/L versus 4.25 ± 1.18 mmol/L, q = 0.0453) levels compared to non-carriers. In the 70–79 age group, ROC curve analysis showed that TG (AUC = 0.65, 95%CI = 0.514–0.785, p = 0.046), LDL-C (AUC = 0.663, 95%CI = 0.526–0.801, p = 0.03) and CHOL (AUC = 0.692, 95%CI = 0.557–0.827, p = 0.011) had certain reference value for diagnosis. Among patients presenting with rapid eye movement sleep behavior disorder, fluctuating cognition, and parkinsonism, APOE ε4 carriers exhibited higher levels of APO B, CHOL, and LDL-C compared to non-carriers.
Conclusions
Peripheral blood lipid level as a metabolic biomarker, combined with APOE ε4 gene detection, has potential value for disease monitoring and prognosis evaluation.
KramerMLSchulz-SchaefferWJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci2007; 27: 1405–1410.
2.
ZhangHDaiSYangY, et al.Role of sirtuin 3 in degenerative diseases of the central nervous system. Biomolecules2023; 13: 735.
3.
BonanniLThomasAOnofrjM. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology2006; 66: 1455. author reply 1455.
4.
McKeithIGGalaskoDKosakaK, et al.Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47: 1113–1124.
5.
LiddelowSAGuttenplanKAClarkeLE, et al.Neurotoxic reactive astrocytes are induced by activated microglia. Nature2017; 541: 481–487.
6.
LinKJLinKLChenSD, et al.The overcrowded crossroads: mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson's disease. Int J Mol Sci2019; 20: 5312.
7.
MahleyRWRallSCJr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet2000; 1: 507–537.
8.
WilsonCMauTWeisgraberKH, et al.Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure1994; 2: 713–718.
9.
WilsonCWardellMRWeisgraberKH, et al.Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science1991; 252: 1817–1822.
10.
WeisgraberKH. Apolipoprotein E: structure-function relationships. Adv Protein Chem1994; 45: 249–302.
11.
DavignonJGreggRESingCF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis1988; 8: 1–21.
12.
MahleyRWJiZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res1999; 40: 1–16.
13.
BuG. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci2009; 10: 333–344.
14.
LiuCCLiuCCKanekiyoT, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
15.
HarveyJPishvaEChouliarasL, et al.Elucidating distinct molecular signatures of Lewy body dementias. Neurobiol Dis2023; 188: 106337.
16.
MeloTQCopraySFerrariMFR. Alpha-synuclein toxicity on protein quality control, mitochondria and endoplasmic reticulum. Neurochem Res2018; 43: 2212–2223.
17.
ParmeraJBBruckiSNitriniR. Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology2018; 90: 299–300.
18.
BenussiACantoniVGrassiM, et al.Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer's disease. Ann Neurol2022; 92: 322–334.
19.
LibriISilvestriCCaratozzoloS, et al.Association of APOE genotype with blood-brain barrier permeability in neurodegenerative disorders. Neurobiol Aging2024; 140: 33–40.
20.
GlibertBBourleauxVPeetersR, et al.Analytical performance verification of the Beckman Coulter AU5800 Clinical Chemistry Analyser against recognized quality specifications reveals relevance of method harmonization. Clin Lab2016; 62: 57–72.
21.
DietschyJMTurleySD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res2004; 45: 1375–1397.
22.
HuangYMuckeL. Alzheimer mechanisms and therapeutic strategies. Cell2012; 148: 1204–1222.
23.
MahleyRWHuangY. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron2012; 76: 871–885.
24.
MahleyRWWeisgraberKHHuangY. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res2009; 50: S183–188.
25.
DongLMWeisgraberKH. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem1996; 271: 19053–19057.
26.
DongLMWilsonCWardellMR, et al.Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem1994; 269: 22358–22365.
27.
ZerbinattiCVCurtissLKDyerCA. Role of heparan sulfate proteoglycans in the apolipoprotein E modulation of ovarian androgen production. Biol Reprod1998; 58: 165–165.
28.
GreggREZechLASchaeferEJ, et al.Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest1986; 78: 815–821.
29.
LiHDhanasekaranPAlexanderET, et al.Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels. Arterioscler Thromb Vasc Biol2013; 33: 687–693.
30.
WeintraubMSEisenbergSBreslowJL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest1987; 80: 1571–1577.
31.
DelenclosMFaroqiAHYueM, et al.Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun2017; 5: 51.
32.
ZhaoNLiuCCVan IngelgomAJ, et al.APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat Commun2018; 9: 4388.
33.
ZhaoNAttrebiONRenY, et al.APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med2020; 12: eaay1809.
34.
KovacsGGWagnerUDumontB, et al.An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol2012; 124: 37–50.
35.
KovacsGGBreydoLGreenR, et al.Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis2014; 69: 76–92.
36.
ApaydinHAhlskogJEParisiJE, et al.Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol2002; 59: 102–112.
37.
HurtigHITrojanowskiJQGalvinJ, et al.Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology2000; 54: 1916–1921.
38.
KovariEGoldGHerrmannFR, et al.Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol2003; 106: 83–88.
39.
MattilaPMRinneJOHeleniusH, et al.Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol2000; 100: 285–290.
40.
MattilaPMRinneJOHeleniusH, et al.Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol1999; 98: 157–164.
41.
O'BrienJTFirbankMJMosimannUP, et al.Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res2005; 139: 79–88.
42.
PimlottSLPiggottMBallardC, et al.Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiol Dis2006; 21: 50–56.
43.
GentTCBassettiCAdamantidisAR. Sleep-wake control and the thalamus. Curr Opin Neurobiol2018; 52: 188–197.
44.
HattersDMPeters-LibeuCAWeisgraberKH. Apolipoprotein E structure: insights into function. Trends Biochem Sci2006; 31: 445–454.
45.
ZorecRParpuraVVardjanN, et al.Astrocytic face of Alzheimer's disease. Behav Brain Res2017; 322: 250–257.
46.
JeskeDJDietschyJM. Regulation of rates of cholesterol synthesis in vivo in the liver and carcass of the rat measured using [3H]water. J Lipid Res1980; 21: 364–376.
47.
SpagnuoloMSPallottiniVMazzoliA, et al.A short-term Western diet impairs cholesterol homeostasis and key players of beta amyloid metabolism in brain of middle aged rats. Mol Nutr Food Res2020; 64: e2000541.
48.
MeaneySBodinKDiczfalusyU, et al.On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res2002; 43: 2130–2135.
49.
RamirezDMAnderssonSRussellDW. Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol2008; 507: 1676–1693.
50.
TcwJQianLPipaliaNH, et al.Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell2022; 185: 2213–2233 e2225.
51.
AbildayevaKJansenPJHirsch-ReinshagenV, et al.24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem2006; 281: 12799–12808.
